Research programme: ImmunoVEX vaccines - Amgen
Alternative Names: ImmunoVEX-based therapies programmeLatest Information Update: 19 Mar 2011
At a glance
- Originator BioVex
- Developer Amgen; BioVex
- Class Cancer vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Viral infections
- No development reported Human papillomavirus infections
Most Recent Events
- 04 Mar 2011 BioVex has been acquired by Amgen
- 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Vaccines pharmacodynamics section ,
- 18 Jun 2002 Preclinical trials in Herpes simplex virus infections in United Kingdom (unspecified route)